Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes
Main finding · MALOResult — go to the resultHazard ratio 1.04 95% CI 0.88–1.23Authors' conclusion
In this high-risk population with type 2 diabetes, tirzepatide and injectable semaglutide offered comparable effectiveness in mitigating liver disease progression and MALO in the short- to medium-term follow-up.
Study context
- Population
- Adults with overweight or obesity and T2D
- Exposure
- Tirzepatide vs injectable semaglutide
- Outcome
- Time-to-first MALO:
- Cirrhosis
- Decompensated events
- Hepatocellular carcinoma
- Follow-up
- Median ≈17 months
Methodological detailspropensity score matching, TriNetX global network, new-user design
- Propensity score matching
- TriNetX global network
- New-user design
Main finding
MALO
Hazard ratio
1.04
95% CI 0.88–1.23
By group
Tirzepatide
4.05 per 1000 PY
Semaglutide
4.04 per 1000 PY
Tirzepatidevs Semaglutide
HR 1.04 (95% CI 0.88–1.23)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Per 1000 PY
| Outcome | Tirzepatide | Semaglutide | HR (95% CI) | |
|---|---|---|---|---|
| MALO, sensitivity analysis in people with MASLD | 9.97 | 10.03 | 1.03 (0.75–1.42) | |
| MALO, "as treated" analysisAs treated | 0.98 (0.80–1.21) | |||
| 0.512Hazard ratio (log scale) |
| Outcome | Mean difference (kg/m²) | P value |
|---|---|---|
| BMI reductionGreater BMI reduction with tirzepatide | ≈1.1 | P < 0.001 |
Internal validation vs sitagliptin
- Both agents significantly outperformed sitagliptin
Original publication
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes. Obesity (Silver Spring). Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →